will broaden coverage for new Alzheimer's drugs such as Eisai Co Ltd and Biogen Inc's Leqembi if they gain full U.S. approval, a federal agency said on Thursday.
Currently, Medicare, the government health plan for Americans 65 and over, will only pay for Alzheimer's disease drugs approved under the U.S. Food and Drug Administration's rigorous accelerated review if patients are enrolled in a clinical trial. Broader Medicare coverage would begin on the same day the FDA grants traditional approval, the Centers for Medicare & Medicaid Services said.
Leqembi received accelerated approval from the FDA earlier this year and a decision on full approval is due by July 6.that targets amyloid brain plaques, similar to Eisai and Biogen's Leqembi.The company logo for Salesforce.com is displayed on the Salesforce Tower in New York City, U.S., March 7, 2019. REUTERS/Brendan McDermid/
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Elon Musk is once again the world's richest man | CNN BusinessElon Musk has reclaimed his position as the world’s wealthiest person.
Lire la suite »
Elon Musk meets Chinese FM, discusses business expansion in ChinaChina is the world's biggest electric vehicle market, and Tesla announced in April it would build a second massive factory in Shanghai.
Lire la suite »